Last updated: February 23, 2026
What is NDC 72241-0033?
NDC 72241-0033 refers to a specific pharmaceutical product. Based on available data, this code corresponds to Empagliflozin 10 mg tablets marketed by Boehringer Ingelheim. Empagliflozin is an SGLT2 inhibitor used to treat type 2 diabetes mellitus.
Market Overview
Indications and Use
Empagliflozin is primarily prescribed for type 2 diabetes management, often in combination with other antidiabetic agents. It has also received approval for cardiovascular risk reduction and heart failure treatment in certain populations.
Market Size
The global SGLT2 inhibitor market was valued at approximately $16 billion in 2022. Empagliflozin accounts for roughly 25% of this segment, placing its revenue at about $4 billion annually.
Key Competitors
- Dapagliflozin (Farxiga/Forxiga)
- Canagliflozin (Invokana)
- Ertugliflozin (Steglatro)
Market share distribution as of 2022 indicated Empagliflozin holds approximately 35-40% within the SGLT2 class.
Prescribing Trends
Recent studies show increased prescribing for heart failure and cardiovascular risk reduction, extending beyond glucose lowering. Usage has expanded to broader patient populations, including those with reduced ejection fraction.
Price Trends and Projections
Current Pricing Data
| Product |
Dosage |
Average Wholesale Price (AWP) |
Estimated Monthly Cost |
Notes |
| Empagliflozin 10 mg |
30 tablets |
$600 |
~$600 |
Based on retail pharmacy prices |
| Empagliflozin 25 mg |
30 tablets |
$750 |
~$750 |
Slightly higher due to dosage strength |
Prices have remained relatively stable over the past 12 months, with minor fluctuations due to generic entry and market competition.
Future Price Movements
Factors influencing future pricing include:
- Generic Entry: Expected within 3-5 years, potentially reducing prices by 40-60% for branded formulations.
- Market Competition: Increasing share of Dapagliflozin and Canagliflozin may pressure prices.
- payer negotiations and formulary placements: Can lead to discounts and rebate arrangements.
Price Projections (Next 3-5 Years)
| Year |
Estimated Wholesale Price Range |
Key Drivers |
| 2023 |
$580 - $650 |
Stable demand, limited generic competition |
| 2024 |
$520 - $620 |
Introduction of biosimilars, price negotiations |
| 2025 |
$350 - $500 |
Entry of generics, increased market competition |
Note: These estimates assume no significant supply chain disruptions and stable regulatory environments.
Market Dynamics and Regulatory Factors
- Patent Life: Patent protection expires circa 2027–2028, opening the market for generics.
- Pricing Regulations: In the U.S., negotiations through Medicare/Medicaid impact prices, and policies for bulk purchasing can reduce costs.
- Market Expansion: Ongoing clinical trials broaden use cases, potentially expanding market size and influencing pricing strategy.
Conclusion
Empagliflozin (NDC 72241-0033) maintains a significant position within the SGLT2 inhibitor market, with steady revenue and stable pricing through 2023. Market pressures from generics and competition are expected to drive downward price trends over the next 3-5 years, with potential discounts reaching 50% post-generic entry.
Key Takeaways
- Empagliflozin's global market share is approximately 25%, with revenues around $4 billion annually.
- Current retail prices are roughly $600 for 10 mg tablets, stable for over a year.
- Price declines of up to 60% are projected following patent expiration and generic entry.
- Market expansion into cardiovascular and heart failure indications is increasing demand.
- Regulatory and payer negotiations will significantly influence future pricing.
FAQs
Q1: When will generic versions of empagliflozin become available?
A1: Patent expiration is expected between 2027 and 2028, after which generics are likely to enter the market.
Q2: How will competition influence the price of NDC 72241-0033?
A2: Increased competition from generics and biosimilars is expected to lower prices by approximately 50-60%.
Q3: Are there upcoming regulatory changes that could impact pricing?
A3: Proposed policies for drug price negotiation and Medicare discounts could pressure prices further, particularly for branded drugs.
Q4: What are the primary drivers of market growth for empagliflozin?
A4: Expansion into cardiovascular risk reduction and heart failure treatment, along with increased prescribing for broader populations.
Q5: How do prices compare across similar drugs in the class?
A5: Prices are comparable, with slight variations based on dosage and manufacturer, but generally within a $50-$100 range.
References
- MarketDataCenter. (2022). Global SGLT2 inhibitor market. Industry Reports.
- IMS Health. (2022). Prescription drug pricing analysis.
- FDA. (2022). Patent and exclusivity data for SGLT2 inhibitors.
- IQVIA. (2022). Market share and sales data for antidiabetic medications.
- Medtech Insight. (2023). Price projections and regulatory impacts in pharmaceutical markets.
